Key Points
Analysts expect $2.77 EPS and $4.67B revenue on May 7.
BDX shows mixed beat/miss pattern with 50% EPS beat rate.
Declining EPS trend signals margin compression despite stable revenue.
B+ Meyka grade reflects neutral sentiment with limited near-term catalysts.
Becton, Dickinson and Company (BDX) reports earnings on May 7, 2026, with analysts expecting $2.77 earnings per share and $4.67 billion in revenue. The medical device and diagnostic products maker faces a critical test as it navigates pricing pressures and operational challenges. BDX stock has declined 1.46% recently, trading at $144.17 with a market cap of $52.2 billion. Meyka AI rates BDX with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors. Understanding what to expect from this earnings report is essential for investors monitoring healthcare sector performance.
What Analysts Expect from BDX Earnings
Wall Street has set modest expectations for Becton Dickinson’s upcoming earnings report. Analysts project $2.77 earnings per share and $4.67 billion in revenue for the quarter ending May 5, 2026.
EPS Estimate Analysis
The $2.77 EPS estimate represents a significant decline from the previous quarter’s actual $2.91 EPS reported in February 2026. This 4.8% drop signals analyst concerns about profitability headwinds. However, it’s important to note that BDX beat the prior quarter’s $2.21 EPS estimate by 31.7%, demonstrating the company’s ability to exceed expectations when operational conditions align favorably.
Revenue Projection Context
The $4.67 billion revenue estimate falls below the prior quarter’s $5.25 billion actual result. This 11% sequential decline is typical for medical device companies experiencing seasonal patterns. Compared to the February estimate of $5.15 billion, the current projection shows analyst caution about near-term demand. The company’s three-quarter track record shows mixed results: beating revenue estimates in August 2025 ($5.51B actual vs. $5.49B estimate) but missing in February 2026 ($5.25B actual vs. $5.15B estimate).
Analyst Consensus Rating
Three analysts rate BDX as “Buy” while seven recommend “Hold,” reflecting cautious optimism. No analysts rate the stock as “Sell” or “Strong Sell.” This consensus suggests the market views BDX as fairly valued but lacking strong near-term catalysts for significant upside movement.
Historical Earnings Trends and Beat/Miss Patterns
Becton Dickinson’s recent earnings history reveals an inconsistent pattern of beating and missing analyst expectations, which complicates forecasting for this quarter.
Recent Quarter Performance
In the most recent quarter (February 2026), BDX delivered $2.91 EPS against a $2.21 estimate, representing a 31.7% beat. Revenue came in at $5.25 billion versus $5.15 billion estimated, a modest 1.9% beat. This strong performance suggests management can execute when conditions permit. However, the August 2025 quarter showed tighter margins: EPS of $3.68 beat the $3.40 estimate by 8.2%, while revenue of $5.51 billion barely exceeded the $5.49 billion estimate by 0.4%.
Declining EPS Trajectory
The earnings per share trend shows deterioration. The February quarter’s $2.91 EPS was lower than August’s $3.68, indicating sequential pressure. The current $2.77 estimate continues this downward trend, suggesting operational challenges persist. This decline occurs despite revenue remaining relatively stable, pointing to margin compression as the primary concern.
What This Means for May 7
Based on historical patterns, BDX has a 50% beat rate on EPS over the past three quarters. The company tends to beat when revenue estimates are conservative. Given that current revenue guidance appears cautious at $4.67 billion, there’s potential for a modest beat if execution remains solid. However, the declining EPS trend suggests investors should monitor margin commentary closely during the earnings call.
Key Metrics and Financial Health
Understanding BDX’s underlying financial strength provides context for earnings expectations and future performance.
Profitability and Margins
Becton Dickinson maintains a gross profit margin of 45.8%, indicating strong pricing power in its core medical device business. However, the net profit margin of 8.0% reflects significant operating expenses and tax burdens. The operating margin of 12.4% shows the company generates reasonable returns from core operations before financing costs. These margins are healthy for the medical device sector but face pressure from rising manufacturing and distribution costs.
Cash Flow Generation
The company generates $11.91 operating cash flow per share and $9.23 free cash flow per share, demonstrating solid cash conversion. This supports the 2.58% dividend yield and ongoing capital investments. The debt-to-equity ratio of 0.77 indicates moderate leverage, providing financial flexibility for acquisitions or shareholder returns.
Valuation Metrics
BDX trades at a P/E ratio of 23.55, above the historical average, suggesting the market prices in future growth. The price-to-sales ratio of 2.40 is reasonable for a healthcare company with recurring revenue streams. The price-to-book ratio of 1.63 indicates the stock trades at a modest premium to tangible assets, typical for established medical device manufacturers.
What Investors Should Watch During Earnings
Several key items will determine whether BDX meets, beats, or disappoints on May 7, 2026.
Segment Performance Breakdown
Investors should monitor performance across BDX’s three segments: BD Medical (syringes, catheters, infusion systems), BD Life Sciences (diagnostics, laboratory automation), and BD Interventional (surgical products). The Medical segment typically drives volume, while Life Sciences provides higher margins. Any segment weakness could explain margin pressure and guide future expectations.
Guidance and Forward Outlook
Management’s guidance for the remainder of fiscal 2026 will be critical. If BDX maintains or raises full-year EPS guidance despite near-term headwinds, it signals confidence in operational improvements. Conversely, guidance cuts would confirm margin concerns and likely pressure the stock. Watch for commentary on pricing actions, cost inflation, and demand trends across geographies.
Operational Efficiency Initiatives
BDX has undertaken restructuring efforts to improve profitability. Investors should ask about progress on cost reduction programs, manufacturing optimization, and supply chain improvements. Success here could support margin recovery in coming quarters, offsetting current pressure.
International and Geographic Mix
With operations worldwide, currency fluctuations and regional demand variations impact results. Management commentary on emerging markets, Europe, and Asia-Pacific regions will help investors assess growth sustainability and exposure to economic slowdowns in key markets.
Final Thoughts
Becton Dickinson’s May 7 earnings report faces moderate expectations with projected $2.77 EPS and $4.67 billion revenue, both declining sequentially. The B+ Meyka AI grade reflects neutral sentiment and fair valuation. Investors should monitor segment performance, management guidance, and margin recovery efforts. The 23.55 P/E ratio leaves limited room for disappointment. Success hinges on demonstrating operational efficiency improvements and stabilizing profitability trends amid mixed beat/miss history.
FAQs
What EPS and revenue does Wall Street expect from BDX on May 7?
Analysts expect $2.77 EPS and $4.67 billion in revenue. EPS is down 4.8% from the prior quarter’s $2.91 actual, while revenue is down 11% sequentially, reflecting typical seasonal patterns in medical device markets.
Has BDX beaten earnings estimates recently?
Yes, BDX beat EPS estimates in the last two quarters: $2.91 actual vs. $2.21 estimate (31.7% beat) in February 2026, and $3.68 actual vs. $3.40 estimate (8.2% beat) in August 2025. Declining EPS suggests margin pressure persists.
What is the Meyka AI grade for BDX and what does it mean?
Meyka AI rates BDX with a B+ grade, indicating neutral sentiment. This factors in S&P 500 comparison, sector performance, financial growth, and analyst consensus. The rating suggests BDX is fairly valued with limited near-term upside catalysts.
What should investors watch during the BDX earnings call?
Focus on segment performance, full-year 2026 guidance, margin recovery initiatives, and geographic demand trends. Commentary on pricing, cost inflation, and operational efficiency will signal whether profitability pressure is temporary or structural.
Is BDX stock overvalued at current levels?
At a 23.55 P/E ratio and 2.40 price-to-sales ratio, BDX trades at a modest premium typical for healthcare companies. Limited room for earnings disappointment makes execution critical for stock performance.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)